We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • Topics
  • Nutra-Q Directory
  • Magazine
  • e-Learning Tools
  • Advertise

Modern Medicine Network
  • Login
  • Register
Skip to main content
  • Login
  • Register
Menu
User
Home
  • Topics
  • Nutra-Q Directory
  • Magazine
  • e-Learning Tools
  • Advertise

SUBSCRIBE: eNewsletter | Magazine

FDA Releases Guidance on Best Practices for Convening GRAS Panels

  • Photo © iStockphoto.com/istocksdaily

  • Kimberly J. Decker
Dec 13, 2017
  • Regulatory, Trends & Business

In a move that some critics of the GRAS system hail as much needed, FDA has issued a draft guidance outlining best practices for putting together an expert panel for evaluating whether or not a substance is Generally Recognized as SAFE (GRAS) for its intended use. The draft guidance is open for public comment until May 15, 2018.

The Federal Food, Drug, and Cosmetic Act waives premarket review and FDA approval for substances deemed GRAS as food additives. But for a substance to qualify as GRAS either via self-affirmation or FDA review, a body of qualified experts must broadly recognize its safe use in food.

In its draft guidance, FDA recommends best practices including identifying GRAS panel members with appropriate and balanced expertise; reducing the risk of bias or the appearance thereof by assessing potential manners for potential or even perceived conflicts of interest; and limiting the data and information provided to the panel to what is also available to the rest of the public.

The draft guidance also reminds interested parties that use of a GRAS panel does not necessarily guarantee that GRAS criteria have been met. It reiterates that for a substance to be GRAS under its intended use conditions, that use must meet the same safety standard as for a food additive—that is, there must be reasonable certainty of no harm under the intended use conditions. Further, the substance’s use must meet the general recognition standard: the substance’s intended food use must be recognized as safe by qualified experts based on publicly available scientific information.

Related Articles

  • P&G to Acquire Merck Consumer Health Business, Including Vitamin and Dietary Supplement Brands in Europe, Asia, and Latin America
  • Ingestible Skincare for Men Is a Growing Market, New Consumer Research Suggests
  • Palmitic Acid Ingredient May Reduce Pain, Inflammation
  • Emergen-C Brand Adding Probiotics to Product Line
  • BioCell Collagen Gets Halal Certifications

Fun Facts

Fun Fact!

Weekly Fun Facts about nutrition and ingredients, courtesy of Nutritional Outlook's editors

Current Issue

Nutritional Outlook Vol. 21, No 3
Apr 01, 2018 Vol 21 No 3
Digital Edition
Connect with Us
  • Twitter
  • Facebook
  • Google+
  • LinkedIn
  • RSS
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.